Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Bought by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP grew its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 45.5% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 472,929 shares of the company’s stock after purchasing an additional 147,907 shares during the period. Dimensional Fund Advisors LP owned approximately 0.47% of Neurocrine Biosciences worth $65,097,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also modified their holdings of the business. RFP Financial Group LLC raised its holdings in Neurocrine Biosciences by 346.5% in the 1st quarter. RFP Financial Group LLC now owns 192 shares of the company’s stock valued at $26,000 after buying an additional 149 shares during the period. Mather Group LLC. purchased a new stake in shares of Neurocrine Biosciences in the 1st quarter valued at approximately $26,000. Ashton Thomas Private Wealth LLC acquired a new position in shares of Neurocrine Biosciences in the 2nd quarter worth approximately $28,000. Innealta Capital LLC purchased a new position in shares of Neurocrine Biosciences during the 2nd quarter worth approximately $30,000. Finally, New Covenant Trust Company N.A. acquired a new stake in Neurocrine Biosciences in the 1st quarter valued at approximately $32,000. 92.59% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, Director Gary A. Lyons sold 930 shares of the business’s stock in a transaction dated Tuesday, July 16th. The shares were sold at an average price of $150.03, for a total transaction of $139,527.90. Following the transaction, the director now directly owns 119,047 shares in the company, valued at $17,860,621.41. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, insider Ingrid Delaet sold 273 shares of the firm’s stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $147.70, for a total value of $40,322.10. Following the completion of the sale, the insider now owns 6,607 shares in the company, valued at $975,853.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Gary A. Lyons sold 930 shares of the company’s stock in a transaction dated Tuesday, July 16th. The stock was sold at an average price of $150.03, for a total transaction of $139,527.90. Following the transaction, the director now owns 119,047 shares in the company, valued at $17,860,621.41. The disclosure for this sale can be found here. Insiders sold a total of 71,798 shares of company stock valued at $10,676,096 over the last three months. 4.30% of the stock is currently owned by company insiders.

Neurocrine Biosciences Stock Performance

NASDAQ NBIX opened at $115.06 on Friday. The firm’s fifty day moving average is $136.11 and its two-hundred day moving average is $137.61. Neurocrine Biosciences, Inc. has a one year low of $103.63 and a one year high of $157.98. The firm has a market cap of $11.58 billion, a PE ratio of 31.75 and a beta of 0.37.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings results on Thursday, August 1st. The company reported $0.63 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.15 by ($0.52). Neurocrine Biosciences had a net margin of 16.00% and a return on equity of 14.86%. The company had revenue of $590.20 million during the quarter, compared to analyst estimates of $545.98 million. During the same quarter last year, the firm earned $0.95 EPS. The business’s revenue was up 30.4% on a year-over-year basis. Research analysts predict that Neurocrine Biosciences, Inc. will post 4.19 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. Piper Sandler upgraded Neurocrine Biosciences from a “neutral” rating to an “overweight” rating and raised their price target for the stock from $131.00 to $159.00 in a research report on Thursday, August 29th. Morgan Stanley lifted their target price on Neurocrine Biosciences from $160.00 to $170.00 and gave the company an “overweight” rating in a research report on Friday, July 12th. Oppenheimer increased their price target on shares of Neurocrine Biosciences from $216.00 to $219.00 and gave the stock an “outperform” rating in a research report on Friday, August 2nd. Needham & Company LLC restated a “hold” rating on shares of Neurocrine Biosciences in a report on Thursday, August 29th. Finally, Jefferies Financial Group upped their target price on shares of Neurocrine Biosciences from $177.00 to $189.00 and gave the stock a “buy” rating in a research note on Monday, August 19th. Five equities research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Neurocrine Biosciences presently has an average rating of “Moderate Buy” and a consensus price target of $162.20.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.